ORPHA:141209
Generalized lymphatic anomaly
Also known as: Diffuse lymphangioma · Diffuse lymphangiomatosis · Disseminated lymphangioma · Disseminated lymphangiomatosis · Disseminated lymphatic malformation · GLA · Diffuse lymphatic malformation
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
451
85.9th percentile
Trials
0
Interventional, condition-specific
Researchers
1,003
Distinct authors in sample
Gene link
ARAF
Limited
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare developmental defect during embryogenesis characterized by multifocal dilated lymphatic vessels involving multiple organs and tissues. Patients mostly present in infancy and childhood. Clinical course and prognosis depend on the affected sites and extent of the condition, deterioration of lung function being a major cause of morbidity and mortality.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015408
- UMLS:C3839921
Additional Mondo synonyms (8)
Gla · diffuse lymphangioma · diffuse lymphangiomatosis · disseminated lymphangioma · disseminated lymphangiomatosis · disseminated lymphatic malformation · generalised lymphatic anomaly · generalized lymphatic anomaly
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Limited — ARAF
- LiteraturePresent
451 matched papers (326 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for ARAF.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
451
451 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
451 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
326 in the last 10 years · medium confidence · 85.9th percentile (publications denominator)
Phrase hits: 451 · MeSH hits: 0
Who's working on it?
1,003
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ozeki M13 papers · 2025
Department of Pediatrics, Graduate School of Medicine, Gifu University, 1-1, Yanagido, Gifu, 501-1194, Japan. michioo@gifu-u.ac.jp.
Papers in Europe PMC - 02Adams DM9 papers · 2025
Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Papers in Europe PMC - 03Fukao T8 papers · 2019
Department of Pediatrics, Graduate School of Medicine, Gifu University, 1-1, Yanagido, Gifu, 501-1194, Japan.
Papers in Europe PMC - 04Le Cras TD7 papers · 2026
Division of Pulmonary Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Papers in Europe PMC - 05Hammill AM6 papers · 2025
Hemangioma and Vascular Malformation Center, Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Papers in Europe PMC - 06Ji Y6 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, #37# Guo-Xue-Xiang, Chengdu, 610041, China. jijiyuanyuan@163.com.
Papers in Europe PMC - 07Iacobas I5 papers · 2022
TCH Vascular Anomalies Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
Papers in Europe PMC - 08Nozawa A5 papers · 2024
Department of Pediatrics, Graduate School of Medicine, Gifu University, 1-1, Yanagido, Gifu, 501-1194, Japan.
Papers in Europe PMC - 09Zhang Y5 papers · 2025
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 10Al-Ibraheemi A4 papers · 2023
Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT02399527·RECRUITING·Lymphatic Anomalies Registry for the Assessment of Outcome Data
Conditions: Lymphatic Malformation · Generalized Lymphatic Anomaly (GLA) · Central Conducting Lymphatic Anomaly · CLOVES Syndrome·Matched via name phrase
- NCT03001180·RECRUITING·Identification of Biomarkers for Patients with Vascular Anomalies
Conditions: Vascular Anomaly · Generalized Lymphatic Anomaly · Kaposiform Hemangioendothelioma · Kaposiform Lymphangiomatosis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Generalized lymphatic anomaly" OR "Diffuse lymphangioma" OR "Diffuse lymphangiomatosis" OR "Disseminated lymphangioma" OR "Disseminated lymphangiomatosis" OR "Disseminated lymphatic malformation" OR "Diffuse lymphatic malformation" OR "generalised lymphatic anomaly"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Generalized lymphatic anomaly" OR "Diffuse lymphangioma" OR "Diffuse lymphangiomatosis" OR "Disseminated lymphangioma" OR "Disseminated lymphangiomatosis" OR "Disseminated lymphatic malformation" OR "Diffuse lymphatic malformation" OR "generalised lymphatic anomaly" OR "ARAF" OR "lymphatic vessel neoplasm"
Recall-expansion terms: ARAF, lymphatic vessel neoplasm
Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: GLA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T07:55:28.318Z